Let’s connect at @jpmorgan Week 2027!
I’m looking forward to returning to San Francisco, January 11 to 14, and connecting with investors, strategic partners, and colleagues across the life sciences community.
#JPMWEEK27 #JPM2027 #JPMWeek #biopartnering app.sosha.ai/s/qwBPhFqd
Why is CC16 attracting growing interest in respiratory research?
Looking forward to new findings being presented next week at #ERSCongress examining the relationship between CC16 and respiratory health in young adults.
#RespiratoryMedicine #Asthma #COPD
🤖 Made with AI
Looking forward to participating in #RESISanDiego and connecting with investors & strategic partners.
@AspiroTx is developing an inhaled peptidomimetic therapy that mimics the protective power of CC16.
Attending #RESISanDiego, let’s connect.
#biotech #COPD #ASthama @LSciNation
On #WorldAsthmaDay, we recognize the need to go beyond symptom control. Patients need therapies that address the disease, not just flare ups.
@AspiroTx We are working toward restoring lung function & preventing disease progression.
#AsthmaAwareness #RespiratoryHealth #Biotech
Heading to @atscommunity Respiratory Innovation Summit next month in Orlando.
We will be presenting new data showing a key step forward for our program, with a stable aerosol formulation enabling consistent delivery to the lung.
#ATS2026 #RIS2026 #Biotech
Excited to attend Investival Showcase March 10–11
@AspiroTx is developing an inhaled, disease-modifying therapy for asthma and COPD by mimicking the protective biology of CC16.
Meeting with investors to discuss early-stage therapeutic development.
#InvestivalUSA #Biotech
Joining ABD Capital Connect at #JPMWeek2026 to share Aspiro’s progress in respiratory innovation. In SF? Let’s connect.
@AspiroTx #copd #asthma #Biotech
James Lovgren retweeted
Today we recognize the millions living with COPD, a leading cause of morbidity & mortality.
Up to 70% of adults with COPD remain undiagnosed
We’re developing a therapy to reduce inflammation, strengthen epithelial defenses, and modify disease progression💙
#WorldCOPDDay #COPD
James Lovgren retweeted
🌍 World Lung Day 🌍
We stand with patients, caregivers, & all working toward healthier breathing for all. 💙
Aspiro Therapeutics is developing an inhaled CC16 therapy to reduce inflammation, strengthen defenses, and change the course of disease.
#WorldLungDay #COPD #Asthma
James Lovgren retweeted
Early COPD is getting long overdue attention. This CNN piece highlights how lung damage can begin decades before diagnosis.
At Aspiro, we are developing an inhaled CC16-based therapy targeting these early pathways. @katiahetter @CNN
🔗 edition.cnn.com/2025/08/28/h…
Excited to join #RESIBoston next month for 3 days of hybrid partnering across biotech and diagnostics.
I’ll be in Boston all week for Biotech Week (Sept 16–19). Let’s connect if you’re focused on respiratory innovation or early-stage biotech.
resiconference.com/resi-bost…
1
30
James Lovgren retweeted
We’re proud to share that Dr. Stefano Guerra and @Dr_Ledford Ledford, two of our co-founders, are contributing to NIH-funded research on CC16 and early COPD. Dr. Guerra leads the $3.8M NIAID study with Dr. Ledford as co-investigator. #COPD #NIH #Biotech
research.arizona.edu/news/38…
GSK’s $12B COPD deal highlights the value of first in class respiratory innovation. At @AspiroTx , we are developing a CC16 inspired inhaled therapy to modify disease in asthma and COPD, not just manage symptoms.
fiercebiotech.com/biotech/gs…
#biotech #COPD #asthma #respiratoryhealth
James Lovgren retweeted
We’re excited to welcome @MattBritz and Dr. Anne Dixon as advisors to Aspiro! Matt brings deep biotech leadership, and Anne is a leading pulmonary expert. Their guidance will support our CC16-based approach for asthma and COPD.
🔗 buff.ly/y43uYui
#biotech #asthma #COPD
James Lovgren retweeted
Excited to share that Aspiro Therapeutics has been selected to present at the #BIO2025 Startup Stadium in Boston!
@JamesLovgren will present our inhaled therapy inspired by CC16,
Join us Thurs, June 19. Let’s connect.
#StartupStadium #Biotech #COPD #Asthma #RespiratoryHealth
James Lovgren retweeted
We’re just days away! Aspiro CEO @JamesLovgren will present at #RIS2025 this Saturday, May 17 at 2:00 PM PT.
Join us as we share our CC16-driven approach to transforming care for COPD & asthma. 🌬️
🔗 Agenda: conference.thoracic.org/prog…
#COPD #Asthma #Biotech #ATS2025
James Lovgren retweeted
On #WorldAsthmaDay, we stand with millions living with asthma—and the urgent need for better care.
At Aspiro, we’re developing a therapy inspired by the body’s own defenses to restore lung function and prevent progression.
#asthma #CC16 #biotechforgood #WorldAsthmaDay2025
Looking forward to presenting Aspiro’s innovative, CC16-driven science at the 2025 Respiratory Innovation Summit next month!
Excited to share that Aspiro CEO @JamesLovgren will present at #RIS2025 on Saturday, May 17 at 2:00 PM PT in San Francisco! We’re honored to be a Showcase Company advancing new solutions in #respiratoryhealth. 🌬️
Agenda: conference.thoracic.org/prog…
#ATS2025 #COPD #Asthma #Biotech
38
James Lovgren retweeted
Excited to share that Aspiro CEO @JamesLovgren will present at #RIS2025 on Saturday, May 17 at 2:00 PM PT in San Francisco! We’re honored to be a Showcase Company advancing new solutions in #respiratoryhealth. 🌬️
Agenda: conference.thoracic.org/prog…
#ATS2025 #COPD #Asthma #Biotech
James Lovgren retweeted
Biotech Venture Creation: The Benefits Of Scarcity.
The equity markets have collapsed in 2025, the IPO window is closed, the FDA is in turmoil, the NIH is being gutted… and it’s a great time to start new biotech companies.
lifescivc.com/2025/04/biotec…
















